mRESVIA
Vaccine
Evidence outlook
Approved: Respiratory Syncytial Virus Infection
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Prevention of disease caused by RS virus infection
- Protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RSVictory NCT05330975 · Respiratory Syncytial Virus Infection Parts A and B were randomized and observer-blinded with active comparison groups, but the primary measures were antibody levels, a laboratory marker of immune response rather than RSV illness. One of the primary non-inferiority tests (RSV-A seroresponse when given with the flu vaccine) did not meet its margin, while the others did. Registry: NCT05330975 | 3 | Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection; Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection (Day 1 through Day 28 (28 days after Day 1 injection)); Part A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to Withdrawal (Day 1 through Day 181 (end of Study Part A)); Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29; Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29; Part A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29; Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection; Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection; Part B: Number of Participants With Unsolicited AEs After Day 1 Injection (Day 1 through Day 28 (28 days after Day 1 injection)); Part B: Number of Participants With Unsolicited AEs After Day 29 Injection (Day 29 through Day 57 (28 days after Day 29 injection)); Part B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to Withdrawal (Day 1 through Day 211); Part B: GMT of Serum RSV-A at Day 29; Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29; Part B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29; Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29; Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1 (Within 7 days after Day 1 revaccination); Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1 (Revaccination Day 1 through Day 28 (28 days after revaccination Day 1)); Part C: Number of Participants With MAAEs (Revaccination Day 1 through Day 181); Part C: Number of Participants With SAEs, AESIs, and AEs Leading to Withdrawal (Revaccination Day 1 through Day 361); Part C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29 (Primary Vaccination Day 29 to Revaccination Day 29) 2024-11-08 | Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses). | Partial signal | link ↗ |
View 1 more trial
NCT06060457 NCT06060457 · Respiratory Syncytial Virus Infection Registry: NCT06060457 | 3 | Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection; Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection; Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection; Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection; Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation (Day 1 through Day 202); Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs) (Day 22 (for Arm 1) and Day 43 (for Arm 2)); GMT of Serum Anti-Hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay (Day 22) 2024-06-07 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Respiratory Syncytial Virus Infection: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| mRESVIA: this drug | Approved | Vaccine | RSV pre-F protein | Partial signal | NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses). | |
| Clesrovimab (Enflonsia) | Approved | Monoclonal antibody | RSV F protein | not yet graded | No reviewed efficacy summary in this indication | |
| EDP-323 | Phase 2 | Small molecule | RSV L protein | Partial signal | NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743) | |
| Zelicapavir | Phase 2 | Small molecule | RSV N protein (nucleoprotein) | Weak signal | NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants | |
| GSK5893818 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0256 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0291 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0340 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication | |
| SP0341 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow mRESVIA to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.